Literature DB >> 15672050

Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: efficacy vs. incidence of stricture after treatment.

Masoud Panjehpour1, Bergein F Overholt, Mary N Phan, John M Haydek.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) may be used to ablate high-grade dysplasia/early stage cancer (HGD/T1) in patients with Barrett's esophagus. PDT may result in esophageal stricture. This nonrandomized, unblinded, dose de-escalation study in consecutive patients was designed to determine the lowest light dose effective for ablation of HGD/T1 while reducing the incidence of stricture.
METHODS: A total of 113 patients received an injection of porfimer sodium (2 mg/kg). Three days later, 630 nm light was delivered by using a 20-mm-diameter PDT balloon at doses of 115 J/cm (n=59), 105 J/cm (n=18), 95 J/cm (n=17), or 85 J/cm (n=19). Treatment efficacy was determined by obtaining biopsy specimens of the treated area 3 months later. The incidence of stricture was determined by the need for esophageal dilation to treat dysphagia. A stricture was considered severe if 6 or more dilations were required.
RESULTS: The incidence of severe stricture was related to the light dose. At 115 J/cm, 15.3% of patients developed severe strictures compared with 5.3% to 5.6% of those treated with the lower doses. At a light dose of 115 J/cm, 17.0% of patients had residual HGD/T1. Light doses of 105 J/cm, 95 J/cm, and 85 J/cm resulted in residual HGD/T1 in 33.3%, 29.4%, and 31.6% of patients, respectively. None of the observations were statistically significant.
CONCLUSIONS: Decreasing the light dose below 115 J/cm appeared to result in a reduced incidence rate of severe stricture but higher relative frequencies of residual HGD/T1 in Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672050     DOI: 10.1016/s0016-5107(04)02394-6

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  8 in total

Review 1.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

2.  Two-dimensional singlet oxygen imaging with its near-infrared luminescence during photosensitization.

Authors:  Bolin Hu; Nan Zeng; Zhiyi Liu; Yanhong Ji; Weidong Xie; Qing Peng; Yong Zhou; Yonghong He; Hui Ma
Journal:  J Biomed Opt       Date:  2011 Jan-Feb       Impact factor: 3.170

3.  Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Authors:  Hector R Nava; Shyam S Allamaneni; Thomas J Dougherty; Michele T Cooper; Wei Tan; Gregory Wilding; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

Review 4.  Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.

Authors:  Baozhong Zhao; Yu-Ying He
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

5.  Self-expandable metal stents and trans-stent light delivery: are metal stents and photodynamic therapy compatible?

Authors:  Luo-Wei Wang; Li-Bo Li; Zhao-Shen Li; Yang K Chen; Fred W Hetzel; Zheng Huang
Journal:  Lasers Surg Med       Date:  2008-11       Impact factor: 4.025

6.  Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma.

Authors:  Bashar J Qumseya; Waseem David; Herbert C Wolfsen
Journal:  Clin Endosc       Date:  2013-01-31

7.  Pulsed diode laser-based monitor for singlet molecular oxygen.

Authors:  Seonkyung Lee; Leyun Zhu; Ahmed M Minhaj; Michael F Hinds; Danthu H Vu; David I Rosen; Steven J Davis; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

8.  How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus.

Authors:  Gary D Mackenzie; Neil F Jamieson; Marco R Novelli; C Alexander Mosse; Benjamin R Clark; Sally M Thorpe; Stephen G Bown; Laurence B Lovat
Journal:  Lasers Med Sci       Date:  2007-07-03       Impact factor: 3.161

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.